Alogliptin benzoate is a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an oral anti-diabetic medication to improve glycemic control in adults with type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme,… Read more















Alogliptin benzoate is a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an oral anti-diabetic medication to improve glycemic control in adults with type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, this agent increases the levels of incretin hormones, which helps the body regulate insulin secretion and suppress glucagon release. To ensure the safety and efficacy of this therapeutic, analytical laboratories rely on a comprehensive range of related compounds, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled standards. These high-quality reference materials are essential for impurity profiling, method validation, and rigorous quality control testing during the development and manufacturing of drug products. Using these precisely characterized standards allows researchers to accurately identify, quantify, and monitor potential degradants and by-products, ensuring compliance with strict regulatory requirements throughout the pharmaceutical lifecycle.